临床药物治疗杂志
臨床藥物治療雜誌
림상약물치료잡지
CLINICAL MEDICATION JOURNAL
2014年
z1期
52-56
,共5页
乳腺癌%靶向治疗%内分泌治疗%抗HER2药物%EGFR%VEGF
乳腺癌%靶嚮治療%內分泌治療%抗HER2藥物%EGFR%VEGF
유선암%파향치료%내분비치료%항HER2약물%EGFR%VEGF
breast cancer%targeted therapy%endocrine therapy%the HER2 drug%EGFR%VEGF
目的：通过文献复习探讨乳腺癌的分子靶向治疗现状和进展。方法：查询近几年国内外乳腺癌分子靶向药物治疗进展的关键性文献并进行分析。结果：在乳腺癌的治疗中有明显疗效的分子靶向药物有人表皮生长因子受体2（HER2）的抗靶点药物曲妥珠单抗、拉帕替尼、帕妥珠单抗和曲妥珠单抗一DMl；有表皮生长因子受体( EGFR)靶向治疗的药物吉非替尼和西妥昔单抗，其他的靶点药物有血管内皮生长因子(VEGF)的靶向治疗(贝伐珠单抗)等。结论：目前不少分子靶向药物进入乳腺癌的临床应用，明显降低了乳腺癌患者的疾病复发风险，延长了晚期乳腺癌患者的生存期，其中抗HER2的靶向药物曲妥珠单抗是乳腺癌治疗最成功的靶向药物。分子靶向治疗是乳腺癌术后辅助治疗和晚期乳腺癌解救治疗中新的重要治疗手段。
目的：通過文獻複習探討乳腺癌的分子靶嚮治療現狀和進展。方法：查詢近幾年國內外乳腺癌分子靶嚮藥物治療進展的關鍵性文獻併進行分析。結果：在乳腺癌的治療中有明顯療效的分子靶嚮藥物有人錶皮生長因子受體2（HER2）的抗靶點藥物麯妥珠單抗、拉帕替尼、帕妥珠單抗和麯妥珠單抗一DMl；有錶皮生長因子受體( EGFR)靶嚮治療的藥物吉非替尼和西妥昔單抗，其他的靶點藥物有血管內皮生長因子(VEGF)的靶嚮治療(貝伐珠單抗)等。結論：目前不少分子靶嚮藥物進入乳腺癌的臨床應用，明顯降低瞭乳腺癌患者的疾病複髮風險，延長瞭晚期乳腺癌患者的生存期，其中抗HER2的靶嚮藥物麯妥珠單抗是乳腺癌治療最成功的靶嚮藥物。分子靶嚮治療是乳腺癌術後輔助治療和晚期乳腺癌解救治療中新的重要治療手段。
목적：통과문헌복습탐토유선암적분자파향치료현상화진전。방법：사순근궤년국내외유선암분자파향약물치료진전적관건성문헌병진행분석。결과：재유선암적치료중유명현료효적분자파향약물유인표피생장인자수체2（HER2）적항파점약물곡타주단항、랍파체니、파타주단항화곡타주단항일DMl；유표피생장인자수체( EGFR)파향치료적약물길비체니화서타석단항，기타적파점약물유혈관내피생장인자(VEGF)적파향치료(패벌주단항)등。결론：목전불소분자파향약물진입유선암적림상응용，명현강저료유선암환자적질병복발풍험，연장료만기유선암환자적생존기，기중항HER2적파향약물곡타주단항시유선암치료최성공적파향약물。분자파향치료시유선암술후보조치료화만기유선암해구치료중신적중요치료수단。
Objective:To explore the status and research progress of the molecular targeted drugs for treatment of breast cancer .Methods: To view and analyze the data of research advances of molecular targeted drugs in the treatment of breast cancer domesticaly and internationaly in recent years.Results:The drugs have obvious curative effect in the treatment of breast cancer molecular targeted drugs including anti human epidermal growth factor receptor 2(HER2)such as trastuzumab , lapatinib, pertuzumab and T- DM1; anti Epidermal growth factor receptor (EGFR), such as cetuximab;other drugs with targets on vascular endothelial growth factor (VEGF) such as bevacizumab, etc. Conclusion:Currently, many molecular targeted drugs in the clinical treatment of breast cancer, significantly reduce the risk of disease recurrence of patients with breast cancer, prolong the survival period of patients with advanced breast cancer, in which trastuzumab is the most successful targeted drugs in treatment of patients with breast cancer. Molecular target therapy is an important new treatments in treatment of patient with breast cancer.
